+ All Categories
Home > Documents > Karen Livingstone, Director of ...

Karen Livingstone, Director of ...

Date post: 11-Mar-2022
Category:
Upload: others
View: 1 times
Download: 0 times
Share this document with a friend
11
www.sbrihealthcare.co.uk Karen Livingstone, Director of SBRI & EAHSN Industry Engagement & Partnerships
Transcript

www.sbrihealthcare.co.uk Karen Livingstone, Director of SBRI & EAHSN Industry Engagement & Partnerships

www.sbrihealthcare.co.uk

The NHS Innovation Agenda

We will double our investment in the Small Business Research

Initiative to develop innovative solutions to healthcare challenges, encourage greater competition in

procurement of services, and drive growth in the UK SME sector

www.sbrihealthcare.co.uk

Helping the Public Sector address challenges

• Using innovation to achieve a step change

Accelerating technology commercialisation

• Providing a route to market Support and the development of

Innovative companies • Providing a lead customer/R&D

partner • Providing funding and credibility

for fund raising

100% funded R&D Operate under procurement rules

rather than state aid rules UK implementation of EU Pre-

Commercial Procurement Deliverable based rather than

hours worked or costs incurred • Contract with Prime Supplier

Who may choose to sub contract but remains accountable

• IP rests with Supplier Certain usage rights with Public

Sector – Companies encouraged to exploit IP

• Light touch Reporting & payments quarterly & up front

SBRI Key features

www.sbrihealthcare.co.uk

SBRI Process

Problem Identification

Open call to Industry

Feasibility Testing

Prototype development

Typically undertaken by

clinicians – service driven

Workshops with industry to support

understanding

Typically 6 months – max

of £100k

Typically 18 months – milestones agreed

& monitored

Due diligence & contracts

www.sbrihealthcare.co.uk

Case Study:

The system delivers nitric oxide directly to specific skin tissue in order to help increase blood flow and stimulate wound healing. The SBRI funding has meant that we have been able to move from a non-investible company to one that could be invested in. Edixomed has partnered with a wound dressing company in order to bring the product to market in the UK and the dressing is now in clinical trials at Kings College Hospital, London and at Ninewells Hospital in Dundee. Chairman, Mr Wood says the company hope to bring the product to market next year.

The backing and investment from the SBRI

competition has been critical

Edinburgh based Edixomed have developed a Nitric Oxide dressing for diabetic patients with chronic leg ulcers to enable rapid healing

Chris Wood, Chairman

www.sbrihealthcare.co.uk

Case Study:

My belief is that had we not had the SBRI funding we would not have raised additional private equity

funding and had it not been for SBRI validation I don’t think this company would be around now.

Oxford University Spin out Company, Eykona technologies has devised a novel 3D camera which allows for improved monitoring and clinical intervention of chronic wounds in clinics, hospitals and in patient homes.

Peter Bannister, Chief Scientific Officer

The Eykona wound measurement system, which was launched in the UK in December 2011 is already being used in 20 NHS hospitals and primary care settings, allows community nurses to monitor the wounds while having the back-up hospital-based experts. Images can be evaluated without the need for patients to visit outpatients – increasing effectiveness and reducing costs. The technology allows wounds to be assessed by volume

www.sbrihealthcare.co.uk

Case Study:

Huntingdon based start up Aseptika Ltd has devised a home-based rapid quantitative test for bacterial respiratory infections in patients with cystic fibrosis (CF)

The company has successfully demonstrated the feasibility of quantifying the levels of key biomarkers in sputum donated by cystic fibrosis patents as a way of predicting the onset of chest infections known clinically as exacerbations. Evidence indicates that for every day of ‘advanced warning’ and every day an effective antimicrobial is administered, time in the clinic is reduced by 0.5 day. The company is now in the process of scaling up trials to make it possible for CF patients and their doctors to monitor their health at home and they hope to start full clinical trials early next year.

SBRI is a case of relatively small amounts of money making the

difference and being able to develop the new products the

public sector needs and support the development of new

companies.

Dr Kevin Auton, MD

www.sbrihealthcare.co.uk

SME PolyPhotonix has worked with the Liverpool University Hospitals Ophthalmology team to create a LED mask that stops the damage of diabetic retinopathy & wet and dry AMD. Phase II trials are going well and Phase III are commissioned by Moorefield's starting in Sept. PolyPhotonix is pioneering the early adoption of organic light. Working with designers and key customers, it is creating new products and supporting the design process right through to manufacture based at the National Pritable Electronics Centre in Sedgefield.

Case Study:

The company have increased 5 fold and have all their manufacturing in the UK

www.sbrihealthcare.co.uk

Outcomes achieved to date Competition Launch

Date No. of entries received

Contracts Awarded Phase 1 & 2

Value Funding lever- aged

1 DH – Pathogen detection Oct 2008 15 7 2 £2m -

2 DH – Hand Hygiene Oct 2008 38 6 4 £3.1m £3m

3 Managing Long Term Conditions Apr 2009 89 5 2 £1.2 m £3.19 m

3 Patient Safety Apr 2009 46 5 2 £1.25 m £1.25 m

4 Keeping Children Active Apr 2009 42 1 0 £0.1 m -

5 Dementia June 2010 28 7 3 £1.2m -

6 Hospital Admissions June 2010 69 5 2 £0.4m -

7 Long Term Conditions Feb 2011 73 8 5 £2.2 m £3.2 m

8 Medicines Management Apr 2012 49 5 4 £0.5 – +£1.5m phase 2 -

9 Behaviour changes April 2012 108 8 2 £0.68k - +£1.3m phase 2

10 End of Life Jan 2013 97 5 Tbc £2.5m tbc

11 Mental Health Jan 2013 80 4 tbc £2.5m tbc

TOTALS TO DATE 734 66 31 £17.63m £2.8m due £10.64m

www.sbrihealthcare.co.uk

AHSN/SBRI companies Yorks & Humber Halliday James Ltd

East Midlands Monica Healthcare Ltd

Eastern - Aseptika, Bespak,

S.London, Imperial, UCLP ABMS, Pintrack, Therakind, UMotiff

Wessex CreoMedical, Morgan Automation

North East & North Cumbria Polyphotonix Ltd

Kent, Surrey & Sussex Anaxsys, InMezzo

Grter Manchester Cheshire/Merseyside, Lancs & Cumbria - Sky Med, TrusTECH

West Midlands SensST Systems, Just Checking Ltd

West of England SentiProfiling

SW. Penisula Frazer Nash

Oxford - Eykona, Oxford Biosignals, Message Dynamics

Scotland & N Ireland Radisens, Edixomed, TwistDX

www.sbrihealthcare.co.uk

Powerful backers of SBRI ‘the SBIR programme will be used ‘across all societal challenges and the enabling and industrial technologies’

The PM would like to see wider use of the SBRI and would like all plans to set out how they will take advantage of this scheme recognising the aspiration to increase the scale of the programme

European Commission Autumn 12

Nesta June 2010

Prime Minister Oct 12

I am convinced that SBRI has a major role to play in not only stimulating industry and SMEs to innovate, but also in helping the NHS provide better services for patients. It is my belief that SBRI Programmes should be embedded into the innovation architecture that we are building through AHSNs.

Secretary of State for Health Jan 13


Recommended